Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerChristopher J. Sweeney, Robert S. DiPaola, Yu‐Hui Chen et al.|New England Journal of Medicine|2015Cited by 2.8k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED TrialChristos E. Kyriakopoulos, Christopher J. Sweeney, Noah M. Hahn et al.|Journal of Clinical Oncology|2018Cited by 1.1k
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket studyFunda Meric‐Bernstam, John D. Hainsworth, Herbert I. Hurwitz et al.|The Lancet Oncology|2019Cited by 564
Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activationChen-Lin Hsieh, Philip W. Kantoff, Fei Teng et al.|Proceedings of the National Academy of Sciences|2014Cited by 403
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trialThomas Powles, Christopher J. Sweeney, Kobe Yuen et al.|Nature Medicine|2022Cited by 241